Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Ascletis sees no benefit to high, fast oral GLP-1 dose titration
The latest results show a high starting dose, fast titration model provides the same weight loss and worse tolerability than more measured approaches.
Nick Paul Taylor
Apr 23, 2025 7:25am
Lilly's oral GLP-1 delivers Ozempic-like efficacy in phase 3
Apr 17, 2025 6:45am
Novartis culls ph. 2 knee pain trial testing anti-ADAMTS-5 asset
Apr 16, 2025 2:55pm
Telix shows 'promising’ 13-month OS in ph. 2 brain cancer study
Apr 16, 2025 6:30am
Mural's IL-2 flop triggers 90% staff reduction
Apr 15, 2025 9:33am
Sanofi's hopes for $1.1B Kymab drug dented after ph. 2 asthma fail
Apr 15, 2025 7:34am